GLP-1 Medications May Help Quiet “Food Noise”

People living with obesity often describe something called “food noise” — persistent, intrusive thoughts about food that can feel difficult to control and emotionally exhausting. These thoughts may include constantly thinking about meals, cravings, snacking or feeling distracted by food throughout the day. While many patients taking GLP-1 medications have informally reported that these drugs seem to “quiet” food noise, there has been little scientific evidence examining whether that effect is real.

Now, a new study presented at the European Congress on Obesity in Istanbul, Turkey, suggests those reports may have merit. Investigators evaluated whether GLP-1 receptor agonists (GLP-1 RAs), a class of medications increasingly used to treat obesity, reduced food noise more effectively than behavioral weight management alone.

The study followed 417 adults enrolled in a digital behavioral weight management program. Participants either received behavioral treatment alone or behavioral treatment combined with a newly initiated GLP-1 medication. Importantly, none of the participants had been taking GLP-1 drugs or other weight-loss medications before the study began.

To measure food noise, a team of investigators led by Hanim E. Diktas, Ph.D., a postdoctoral research fellow in the Ingestive Behavior, Weight Management and Health Promotion Laboratory at Pennington Biomedical Research Center, used a validated tool called the Food Noise Questionnaire (FNQ), which evaluates how often intrusive thoughts about food interfere with daily life. Participants completed the questionnaire at the start of the study and again one month later.

The results showed that food noise decreased in both groups, suggesting that behavioral support alone can help improve eating-related thoughts and habits. However, the reduction was significantly greater in the group taking GLP-1 medications. Patients using GLP-1 therapy experienced an average drop in food noise scores that was about three points greater than those using behavioral treatment alone.

“Food noise was reduced during weight loss treatment, and initiation of GLP-1 RA drugs was associated with a significantly greater reduction than behavioral treatment alone,” noted investigators. “This substantial reduction in food noise with GLP1 RA drugs, when combined with behavioral treatment, is in line with previous anecdotal findings and may serve as an early indicator of treatment response.”

The team says this finding is important because food noise can make healthy behaviors much harder to maintain over time. Constant cravings and obsessive food thoughts may contribute to emotional eating, overeating, or difficulty sticking with nutrition and exercise goals. By reducing those intrusive thoughts, GLP-1 medications may help some patients feel more in control around food and less mentally consumed by eating decisions.

The study authors note that these results are still early and observational, meaning more long-term randomized clinical trials are needed to confirm the findings. The study population was also primarily White and female, so future research will need to include more diverse groups of patients.

“The current study focused on the one‑month follow-up because it was the first follow-up time point available in this dataset for most participants and provided indication of short-term change in food noise,” concluded investigators. “However, future studies should investigate food noise over a longer follow-up period to understand the mechanistic role of food noise in weight, health and quality of life outcomes.”

Still, the findings offer insight into why many people taking GLP-1 medications report feeling differently around food — not just eating less, but thinking about food less often. Changes in food noise could even become an early sign that treatment is working.